Recent Updates
Recently added Catalysts
ATYR Negative Sentiment Score: 20/100

aTyr Pharma, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – ATYR

Key Takeaway: aTyr Pharma, Inc. is currently facing a class action lawsuit for allegedly violating securities laws by making false and misleading statements regarding the efficacy of its drug candidate, Efzofitimod. The lawsuit highlights concerns over aTyr's claims that their drug could help patients taper off steroid use entirely. Shareholders who acquired shares within the designated class period from January 16, 2025, to September 12, 2025, are urged to contact the DJS Law Group for participation in the case. The deadline for potential lead plaintiff appointments is December 8, 2025.

Market Sentiment Analysis

CONCERNS & RISKS

  • aTyr Pharma is facing a class action lawsuit for alleged securities law violations.
  • The lawsuit claims that aTyr made false and misleading statements about the efficacy of its drug candidate, Efzofitimod.
  • Investors are reminded of the misleading public statements made during the class period, which has led to potential financial losses.

Full Press Release Details

LOS ANGELES, Nov. 13, 2025 (GLOBE NEWSWIRE) -- The DJS Law Group reminds investors of a class action lawsuit against aTyr Pharma, Inc. (“aTyr” or “the Company”) (NASDAQ: ATYR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Shareholders who purchased shares of ATYR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: January 16, 2025 to September 12, 2025
DEADLINE: December 8, 2025
CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. aTyr was overwhelmingly positive in its statements to the market about the efficacy of its drug candidate, Efzofitimod. The Company misled investors about the drug’s potential to help patients completely taper the usage of steroids. Based on these facts, aTyr’s public statements were false and materially misleading throughout the class period.
If you are a shareholder who suffered a loss, contact us to participate.
NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. There is no cost or obligation to you to participate in this case.
WHY DJS LAW GROUP? DJS Law Group’s primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.
Join the case to recover your losses.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
274 White Plains Road, Suite 1
Eastchester, NY 10709

Tags

Frequently Asked Questions

What is the class action lawsuit against aTyr Pharma about?

The lawsuit alleges aTyr Pharma made false statements regarding its drug Efzofitimod's efficacy.

What is the deadline to join the class action against aTyr?

The deadline to join the class action is December 8, 2025.

Who can participate in the aTyr Pharma class action?

Shareholders who purchased shares between January 16, 2025, and September 12, 2025, can participate.

What happens after registering for the aTyr class action?

Upon registration, shareholders receive updates through a portfolio monitoring software.

Why choose DJS Law Group for this class action?

DJS Law Group specializes in securities class actions and aims to enhance investor returns.

Last updated: Nov 13, 2025